Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Short Interest Update

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 349,800 shares, a drop of 83.3% from the February 13th total of 2,100,000 shares. Approximately 3.5% of the shares of the stock are short sold. Based on an average trading volume of 6,960,000 shares, the days-to-cover ratio is currently 0.1 days.

Petros Pharmaceuticals Price Performance

PTPI stock traded down $0.01 during midday trading on Wednesday, reaching $0.09. 7,687,321 shares of the stock were exchanged, compared to its average volume of 2,101,118. Petros Pharmaceuticals has a 52 week low of $0.07 and a 52 week high of $1.67. The company has a fifty day moving average price of $0.25 and a 200 day moving average price of $0.30. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.85 and a quick ratio of 0.74. The stock has a market capitalization of $1.02 million, a PE ratio of -0.02 and a beta of 2.04.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).